Loading
Tissue factor, the clotting trigger, is overexpressed on cervical and several other cancers. Tisotumab vedotin is labelled for cervical cancer without a tissue factor test.
Tisotumab vedotin (Tivdak) is a tissue factor-directed ADC labelled for recurrent or metastatic cervical cancer after chemotherapy (innovaTV 301); the label names tissue factor only as the target and no expression threshold was used in the trials. Its ocular toxicity mirrors mirvetuximab's and requires the same eye care.
In plain words · Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.
No tissue factor test is done before tisotumab vedotin; the drug is given on the basis of the cancer type. Eye drops and regular eye checks are part of the treatment.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“TIVDAK is a tissue factor (TF)-directed antibody and microtubule inhibitor conjugate”
TIVDAK prescribing information (DailyMed)No approval uses this readout as a threshold.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.